ArticleBritish journal of cancer2025

Systemic activation of NRF2 contributes to the therapeutic efficacy of clinically-approved KRAS-G12C anti-cancer drugs.

Liam Baird et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.